GDF15 Protein Drives Brain Cancer Radiation Resistance Through Ferroptosis Suppression
New research reveals how GDF15 protein helps glioblastoma cells survive radiation therapy by blocking ferroptosis cell death.
Summary
Researchers discovered that GDF15, a stress-response protein, enables glioblastoma brain tumors to resist radiation therapy by preventing ferroptosis—a form of iron-dependent cell death. The study found GDF15 levels are significantly higher in radiation-resistant tumor cells and recurrent tumors. GDF15 works by stabilizing the NRF2 protein, which protects cells from oxidative damage, and by promoting immunosuppressive M2 macrophages in the tumor environment. These findings suggest targeting GDF15 could improve radiation therapy effectiveness for this aggressive brain cancer.
Detailed Summary
Glioblastoma (GBM) is the most aggressive form of brain cancer, with poor survival rates despite intensive treatment including surgery, radiation, and chemotherapy. Most patients experience tumor recurrence within months, often at the edges of radiation fields, indicating that some cancer cells survive radiation treatment.
Researchers investigated why certain GBM cells resist radiation by comparing radiation-resistant M059K cells with radiation-sensitive M059J cells. They discovered that GDF15 (Growth Differentiation Factor 15), a stress-response protein, was significantly elevated in resistant cells. Analysis of patient samples confirmed higher GDF15 levels in recurrent tumors compared to primary tumors.
The study revealed GDF15 promotes radiation resistance through two key mechanisms. First, it prevents ferroptosis—a form of programmed cell death triggered by iron-dependent lipid damage. GDF15 stabilizes the NRF2 protein by reducing its degradation, which enhances cellular antioxidant defenses. Cells with reduced GDF15 showed increased lipid peroxidation and ferroptotic cell death after radiation, while GDF15-overexpressing cells were protected.
Second, GDF15 reshapes the tumor's immune environment by promoting M2-type macrophages, which suppress immune responses and support tumor survival. In mouse models, tumors with high GDF15 had more immunosuppressive cells and grew larger after radiation treatment.
Experiments using ferroptosis inhibitors and inducers confirmed that GDF15's protective effects work specifically through ferroptosis suppression. When researchers blocked ferroptosis with ferrostatin-1, GDF15-depleted cells regained radiation resistance. Conversely, inducing ferroptosis with erastin overcame GDF15-mediated protection.
These findings identify GDF15 as a critical mediator of radiation resistance in brain cancer and suggest it could be targeted to improve treatment outcomes and prevent recurrence.
Key Findings
- GDF15 protein levels are significantly higher in radiation-resistant glioblastoma cells and recurrent tumors
- GDF15 prevents radiation-induced ferroptosis by stabilizing NRF2 protein and reducing oxidative damage
- GDF15 promotes M2 macrophage infiltration, creating an immunosuppressive tumor microenvironment
- Targeting GDF15 sensitizes glioblastoma cells to radiation therapy in laboratory and animal models
- Ferroptosis inhibitors can reverse GDF15 depletion effects, confirming the ferroptosis mechanism
Methodology
Researchers used multiple glioblastoma cell lines, patient tumor samples, and mouse models. They employed transcriptomic analysis, protein studies, ferroptosis assays, and immune profiling to establish GDF15's role in radiation resistance.
Study Limitations
The study was conducted primarily in laboratory settings and animal models. Clinical validation in human patients is needed to confirm therapeutic potential and safety of targeting GDF15 in glioblastoma treatment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.